1.9 USD
+0.05 (+2.7%)
1.94 USD
+0.04 (+2.11%)
We assign a fundamental rating of 2 out of 10 to LIFE. LIFE was compared to 530 industry peers in the Biotechnology industry. LIFE may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, LIFE is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
LIFE had negative earnings in the past year.
LIFE had a negative operating cash flow in the past year.
LIFE had negative earnings in each of the past 5 years.
In the past 5 years LIFE always reported negative operating cash flow.
1.2 Ratios
LIFE has a Return On Assets of -47.62%. This is comparable to the rest of the industry: LIFE outperforms 49.74% of its industry peers.
LIFE's Return On Equity of -63.85% is in line compared to the rest of the industry. LIFE outperforms 58.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.62% | ||
| ROE | -63.85% | ||
| ROIC | N/A |
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for LIFE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LIFE does not have a ROIC to compare to the WACC, probably because it is not profitable.
LIFE has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, LIFE has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -4.12, we must say that LIFE is in the distress zone and has some risk of bankruptcy.
LIFE's Altman-Z score of -4.12 is on the low side compared to the rest of the industry. LIFE is outperformed by 61.18% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that LIFE is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.02, LIFE perfoms like the industry average, outperforming 44.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.12 |
ROIC/WACCN/A
WACC8.87%
2.3 Liquidity
LIFE has a Current Ratio of 6.07. This indicates that LIFE is financially healthy and has no problem in meeting its short term obligations.
LIFE's Current ratio of 6.07 is fine compared to the rest of the industry. LIFE outperforms 60.66% of its industry peers.
LIFE has a Quick Ratio of 6.07. This indicates that LIFE is financially healthy and has no problem in meeting its short term obligations.
LIFE has a better Quick ratio (6.07) than 61.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.07 | ||
| Quick Ratio | 6.07 |
3. Growth
3.1 Past
LIFE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.93%, which is quite impressive.
The Revenue for LIFE has decreased by -94.34% in the past year. This is quite bad
The Revenue for LIFE have been decreasing by -67.68% on average. This is quite bad
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
LIFE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.04% yearly.
LIFE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 291.57% yearly.
EPS Next Y2.52%
EPS Next 2Y9.08%
EPS Next 3Y26.27%
EPS Next 5Y35.04%
Revenue Next Year-19.38%
Revenue Next 2Y375.78%
Revenue Next 3Y505.83%
Revenue Next 5Y291.57%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
LIFE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LIFE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LIFE's earnings are expected to grow with 26.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.08%
EPS Next 3Y26.27%
5. Dividend
5.1 Amount
LIFE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.9
+0.05 (+2.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners69.81%
Inst Owner Change-8.02%
Ins Owners12.06%
Ins Owner Change0%
Market Cap129.87M
Revenue(TTM)588.00K
Net Income(TTM)-53.93M
Analysts81.82
Price Target25.09 (1220.53%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.74%
Min EPS beat(2)-2.98%
Max EPS beat(2)4.45%
EPS beat(4)3
Avg EPS beat(4)9.32%
Min EPS beat(4)-2.98%
Max EPS beat(4)22.57%
EPS beat(8)6
Avg EPS beat(8)12.77%
EPS beat(12)7
Avg EPS beat(12)6.02%
EPS beat(16)10
Avg EPS beat(16)4.78%
Revenue beat(2)1
Avg Revenue beat(2)475.98%
Min Revenue beat(2)-100%
Max Revenue beat(2)1051.96%
Revenue beat(4)1
Avg Revenue beat(4)193.76%
Min Revenue beat(4)-100%
Max Revenue beat(4)1051.96%
Revenue beat(8)2
Avg Revenue beat(8)641.07%
Revenue beat(12)2
Avg Revenue beat(12)394.04%
Revenue beat(16)4
Avg Revenue beat(16)382.04%
PT rev (1m)8.85%
PT rev (3m)10.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.98%
EPS NY rev (1m)2.81%
EPS NY rev (3m)-7.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-84.63%
Revenue NY rev (3m)-95.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 220.87 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.54 | ||
| P/tB | 1.54 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.01
BVpS1.24
TBVpS1.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.62% | ||
| ROE | -63.85% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 432.17% | ||
| Cap/Sales | 507.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.07 | ||
| Quick Ratio | 6.07 | ||
| Altman-Z | -4.12 |
F-Score1
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)486.58%
Cap/Depr(5y)301.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
EPS Next Y2.52%
EPS Next 2Y9.08%
EPS Next 3Y26.27%
EPS Next 5Y35.04%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-19.38%
Revenue Next 2Y375.78%
Revenue Next 3Y505.83%
Revenue Next 5Y291.57%
EBIT growth 1Y-25.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.85%
EBIT Next 3Y43.39%
EBIT Next 5Y48.12%
FCF growth 1Y-54.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.21%
OCF growth 3YN/A
OCF growth 5YN/A
ATYR PHARMA INC / LIFE FAQ
What is the ChartMill fundamental rating of ATYR PHARMA INC (LIFE) stock?
ChartMill assigns a fundamental rating of 2 / 10 to LIFE.
Can you provide the valuation status for ATYR PHARMA INC?
ChartMill assigns a valuation rating of 1 / 10 to ATYR PHARMA INC (LIFE). This can be considered as Overvalued.
What is the profitability of LIFE stock?
ATYR PHARMA INC (LIFE) has a profitability rating of 1 / 10.
What is the earnings growth outlook for ATYR PHARMA INC?
The Earnings per Share (EPS) of ATYR PHARMA INC (LIFE) is expected to grow by 2.52% in the next year.